Seegene, Inc. (096530.KQ)
KRW 23550.0
(-1.26%)
KRW 23550.0
(-1.26%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 669.01 Million KRW | -99.63% |
| 2022 | 182.13 Billion KRW | -66.05% |
| 2021 | 536.55 Billion KRW | 6.82% |
| 2020 | 502.28 Billion KRW | 1783.17% |
| 2019 | 26.67 Billion KRW | 164.12% |
| 2018 | 10.09 Billion KRW | 216.86% |
| 2017 | 3.18 Billion KRW | -55.26% |
| 2016 | 7.12 Billion KRW | 5.14% |
| 2015 | 6.77 Billion KRW | -25.9% |
| 2014 | 9.14 Billion KRW | -4.5% |
| 2013 | 9.57 Billion KRW | 5.16% |
| 2012 | 9.1 Billion KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -2.07 Billion KRW | -135.63% |
| 2024 Q2 | 24.04 Billion KRW | 1257.05% |
| 2023 Q2 | -2.53 Billion KRW | -223.76% |
| 2023 Q1 | 2.05 Billion KRW | -20.65% |
| 2023 FY | 669.01 Million KRW | -99.63% |
| 2023 Q4 | 5.83 Billion KRW | 224.73% |
| 2023 Q3 | -4.67 Billion KRW | -84.15% |
| 2022 Q3 | -11.06 Billion KRW | -144.01% |
| 2022 Q2 | 25.15 Billion KRW | -84.8% |
| 2022 Q4 | 2.58 Billion KRW | 123.36% |
| 2022 Q1 | 165.47 Billion KRW | 1.1% |
| 2022 FY | 182.13 Billion KRW | -66.05% |
| 2021 Q1 | 164.62 Billion KRW | -11.72% |
| 2021 Q3 | 92.75 Billion KRW | -19.69% |
| 2021 FY | 536.55 Billion KRW | 6.82% |
| 2021 Q4 | 163.67 Billion KRW | 76.46% |
| 2021 Q2 | 115.49 Billion KRW | -29.84% |
| 2020 Q1 | 33.61 Billion KRW | 496.23% |
| 2020 Q3 | 151.52 Billion KRW | 15.97% |
| 2020 Q4 | 186.48 Billion KRW | 23.07% |
| 2020 FY | 502.28 Billion KRW | 1783.17% |
| 2020 Q2 | 130.65 Billion KRW | 288.64% |
| 2019 FY | 26.67 Billion KRW | 164.12% |
| 2019 Q3 | 5.89 Billion KRW | -42.07% |
| 2019 Q4 | 5.63 Billion KRW | -4.32% |
| 2019 Q2 | 10.17 Billion KRW | 104.8% |
| 2019 Q1 | 4.96 Billion KRW | -11.96% |
| 2018 Q1 | 761.38 Million KRW | -49.05% |
| 2018 FY | 10.09 Billion KRW | 216.86% |
| 2018 Q4 | 5.64 Billion KRW | 135.71% |
| 2018 Q3 | 2.39 Billion KRW | 83.95% |
| 2018 Q2 | 1.3 Billion KRW | 70.9% |
| 2017 Q3 | 1.41 Billion KRW | 39.64% |
| 2017 Q2 | 1.01 Billion KRW | 542.32% |
| 2017 Q1 | -229.09 Million KRW | -105.24% |
| 2017 Q4 | 1.49 Billion KRW | 5.6% |
| 2017 FY | 3.18 Billion KRW | -55.26% |
| 2016 FY | 7.12 Billion KRW | 5.14% |
| 2016 Q1 | 1.22 Billion KRW | 1559.37% |
| 2016 Q2 | 2.04 Billion KRW | 67.18% |
| 2016 Q3 | -508.95 Million KRW | -124.93% |
| 2016 Q4 | 4.36 Billion KRW | 958.46% |
| 2015 Q2 | 1.96 Billion KRW | 15.15% |
| 2015 Q1 | 1.7 Billion KRW | -31.87% |
| 2015 Q4 | 73.58 Million KRW | -97.57% |
| 2015 FY | 6.77 Billion KRW | -25.9% |
| 2015 Q3 | 3.03 Billion KRW | 54.3% |
| 2014 Q1 | 2.43 Billion KRW | 76.11% |
| 2014 FY | 9.14 Billion KRW | -4.5% |
| 2014 Q4 | 2.5 Billion KRW | 2.31% |
| 2014 Q3 | 2.44 Billion KRW | 39.37% |
| 2014 Q2 | 1.75 Billion KRW | -27.89% |
| 2013 Q4 | 1.38 Billion KRW | -44.54% |
| 2013 Q2 | 3.1 Billion KRW | 19.64% |
| 2013 FY | 9.57 Billion KRW | 5.16% |
| 2013 Q3 | 2.49 Billion KRW | -19.66% |
| 2013 Q1 | 2.59 Billion KRW | 20.75% |
| 2012 Q4 | 2.14 Billion KRW | 27.37% |
| 2012 Q3 | 1.68 Billion KRW | 0.0% |
| 2012 FY | 9.1 Billion KRW | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Osang Healthcare Co.,Ltd | 116.43 Billion KRW | 99.425% |
| InBody Co.,Ltd | 36.72 Billion KRW | 98.178% |
| Curexo Inc. | -4.85 Billion KRW | 113.777% |
| i-SENS, Inc. | 3.7 Billion KRW | 81.963% |
| Ray Co., Ltd. | -2.14 Billion KRW | 131.17% |
| Gencurix Inc. | -19.26 Billion KRW | 103.474% |
| Sugentech Inc. | -17.23 Billion KRW | 103.881% |
| L&C Bio Co., Ltd | 48.36 Billion KRW | 98.617% |